Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 25, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

NEW YORK, May 25, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. ("Atossa" or "the Company") announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on...
May 15, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

SEATTLE, May 15, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
May 14, 2018 16:24 ET | Source: Atossa Genetics Inc.

Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT

SEATTLE, May 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
May 14, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update

SEATTLE, May 14, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and...
May 11, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services’ Office on Women’s Health

SEATTLE, May 11, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
May 08, 2018 08:00 ET | Source: Atossa Genetics Inc.

Atossa Genetics Regains NASDAQ Compliance

SEATTLE, May 08, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
May 07, 2018 08:15 ET | Source: Atossa Genetics Inc.

Atossa Genetics Reminds Investors of Today’s Deadline to be a Shareholder of Record

- To be a shareholder of record, investors are advised to own Atossa stock by 4:00 PM ET, Monday, May 7, 2018 to account for two-day settlement - Record date set as May 9, 2018 SEATTLE, May 07,...
May 03, 2018 08:15 ET | Source: Atossa Genetics Inc.

Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth

SEATTLE, May 03, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
April 30, 2018 08:15 ET | Source: Atossa Genetics Inc.

Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study

SEATTLE, April 30, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq:ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods...
April 24, 2018 08:15 ET | Source: Atossa Genetics Inc.

Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

SEATTLE, April 24, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to...